The $25M Bet on Regulatory Arbitrage

Doctronic didn't wait for FDA approval. They got Utah to rewrite the rules for AI prescribing.

The Longitudinal Imaging Problem Nobody's Solving

A weekend project built by a father for his daughter exposes a $3B blind spot in medical imaging.

The Connection Layer

OpenAI and Anthropic aren't building healthcare products. They're building the infrastructure that connects them.

What Benchling's 2026 Report Actually Tells Us

The data tells a more interesting story than the summary.

Why Did Lilly Just Gave Away $1 Billion in AI Models?

Discovery tools are commoditizing. Value is moving downstream.

The Holiday Recap: Dec 23 – Jan 5

Two major acquisitions. One landmark IPO. And a brutal reminder that biology doesn't care about your biomarkers.

Two Updates for 2026

Thinking Folds is expanding. Here's what's changing.

The $70M Bet That AI Can Solve Drug Discovery's Biggest Problem

71% of drugs fail because scientists pick the wrong target. Edison thinks AI can fix that. But Can It?

The $4 Million Problem

How a $25M startup is solving gene therapy's $4 million payment problem

Why J&J is paying a Dutch startup to design proteins with AI

Cradle Bio's AI designs better proteins in fewer experiments—turning biology into an engineering problem.